Relapsing-Remitting Multiple Sclerosis Clinical Trial
Official title:
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional burden. Today assessment of cognitive dysfunction in MS is still based on traditional pencil-paper task tests which are not able to give a true representation of functional burden observed in patients in real life situations. The development of new tools close to these "life situations", i.e. more ecological, are needed to better assess and take in charge cognitive impairment in MS patients. One way to reach this goal is Virtual Reality (VR). VR offers a new human-computer interface paradigm that simulates a realistic 3D environment where the user become immersed and interacts with it. These last ten years VR has known a rapid development in the health domain and has been applied with success to motor rehabilitation, psychiatry and neuropsychology. In this last domain, virtual environment (VE) reproducing activities of daily living have been used to evaluate executive and memory functions as well as attentional or visuospatial processes. Among main VE developed, driving assessment system, navigation skills, cooking behaviors, virtual supermarket have shown better sensitivity to detect functional consequences of cognitive impairment in various neurological and psychiatric disorders than traditional evaluations. In Caen University Hospital, investigators used VE driving system and developed the use of the Virtual Action Planning in a supermarket (VAP-S ; Klinger et al 2004) where a user move to select and buy groceries and other things inside an interactive virtual supermarket using a shopping cart. In a preliminary study investigators have used this virtual interactive tool to evaluate executive functioning in small group of Parkinson's disease and MS patients. Analysis of initial data shows the feasibility of the VAP-S for use with these two kinds of diseases. According to these results investigators planned a new study in Relapsing-Remitting(RR)- MS patients where they compare the use of VE (driving system and the VAP-S) to traditional attentional and executive evaluation for estimate their respective sensitivity to detect cognitive/functional impairment in MS patients. Investigators hope to shown that VR will demonstrate its interest to assess cognitive functions in MS and to develop cognitive rehabilitation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
| Completed |
NCT02293967 -
Mass Balance Study of MT-1303
|
Phase 1 | |
| Terminated |
NCT02222948 -
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Terminated |
NCT01790269 -
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
|
||
| Terminated |
NCT01701856 -
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00525668 -
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00398528 -
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00315367 -
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
|
Phase 4 | |
| Terminated |
NCT04032171 -
Study of Evobrutinib in Participants With RMS
|
Phase 3 | |
| Completed |
NCT01930708 -
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
|
Phase 4 | |
| Completed |
NCT03000647 -
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
|
N/A | |
| Completed |
NCT02205489 -
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
|
Phase 4 | |
| Completed |
NCT02753088 -
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT01466114 -
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|
Phase 2 | |
| Completed |
NCT01244139 -
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT01416155 -
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
| Completed |
NCT00493116 -
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
|
Phase 4 | |
| Terminated |
NCT01706107 -
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
|
||
| Completed |
NCT01943526 -
Ireland Natalizumab (TYSABRI) Observational Program
|